Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

Infertility Clinical Trial

— PREDICT  

Official title:

Effect of Highly Purified Menotrophin and Recombinant Follicle Stimulating (rFSH, Follitrophin Alpha) in Subfertile Female Patients Undergoing IVF on Progesterone Serum Levels During the Follicular Phase and Their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01225835
• Other study ID #: FE999906 CS11
• Secondary ID: 2010-019411-37
• Status: Completed
• Phase: Phase 4
• First received: October 7, 2010
• Last updated: February 17, 2014
• Start date: October 2010
• Est. completion date: June 2013

Study information

• Verified date: February 2014
• Source: Ferring Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This study is aimed to demonstrate that highly purified Menotrophin produces significant lower progesterone serum levels during the follicular phase in comparison to Follitropin alpha in the treatment of subfertile females undergoing an in vitro fertilisation (IVF) and to investigate if the progesterone serum levels might be a useful predictor for the success rate of the ongoing pregnancy rates

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: June 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 34 Years to 42 Years

Eligibility

Inclusion Criteria:

• Signed informed consent

• Subfertile premenopausal female patients eligible for in vitro fertilisation (IVF) treatment

• Aged =34 and =42 years

• Body mass index of >18 and <28 kg/m^2

• Normal pelvic ultrasound at Screening

• No more than two previous gonadotrophin stimulated cycles of IVF or intracytoplasmic sperm injection (ICSI) in the history of infertility treatment (gonadotrophin stimulated cycles not used for IVF or ICSI do not count; Clomifen cycles are no exclusion criterion)

• At least 3 consecutive ovulatory menstrual cycles of 24-35 days

• No fertility stimulating drugs at all

• Sperm of partner classified as normal according to World Health Organisation (WHO) 2010 criteria

• Clinically normal baseline haematology, clinical chemistry, and urinalysis values

• Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within the last 6 months prior to Screening

• Endocrine test results within the clinically normal limits at Screening

Exclusion Criteria:

• Presence of any clinically relevant systemic disease (e.g., insulin-dependent diabetes mellitus)

• A history of or current endocrine disease (excluding treated hypothyreosis), including polycystic ovary syndrome (PCOS) and hyperprolactinaemia

• A history of coagulation disorders

• Persistent ovarian cysts (>3 months)

• A history of hypersensitivity to any of the constituents of the study medication or related compounds

• Diagnosed poor (<3 oocytes) responders to prior gonadotrophin stimulated ART-cycle

• History of severe ovarian hyperstimulation syndrome in former gonadotrophin stimulated assisted reproductive technology (ART)-cycle

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infertility

Intervention

Drug:
• Menotrophin
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
• Follitrophin alpha
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
• Cetrorelix
Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
• Choriongonadotropin
10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
• Progesterone
Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).

Locations

Country	Name	City	State
Germany	Fertility Center Berlin	Berlin
Germany	Praxisklinik Sydow am Gendarmenmarkt	Berlin
Germany	Kinderwunschzentrum Dortmund	Dortmund
Germany	Universitätsklinikum Duesseldorf, Frauenklinik	Dusseldorf
Germany	Praxis für Kinderwunschbehandlung	Erlangen
Germany	NOVUM Zentrum	Essen
Germany	IVF Zentrum	Saar
Germany	Endokrinologikum Ulm	Ulm

Sponsors (2)

Lead Sponsor	Collaborator
Ferring Pharmaceuticals	Ferring Arzneimittel GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Progesterone (P4) Level in the Morning of the Day of Human Chorionic Gonadotrophin (hCG) Administration	Ovulation induction was performed by administration of hCG once three follicles >=17 mm diameter as shown by pelvic ultrasound examination. This outcome compares the serum progesterone level the morning prior to hCG administration across treatment arm, and also by age stratum (<39 years and >=39 years).	approximately day 10	No
Secondary	Receiver Operating Characteristic (ROC) Analysis of Progesterone as Predictor for Ongoing Pregnancy Rate at Day 7 and Day of hCG Administration	The influence of the progesterone level on the ongoing pregnancy rate (in relation to all randomized patients) was determined by means of the receiver operating characteristic (ROC) curve. Youden's Index (sensitivity + specificity -1) has a range of 0-1, with 0.5 indicating a random effect.	Day 7, approximately Day 10 (hCG Administration)	No
Secondary	Percentage of Participants With Ongoing Pregnancy	Ongoing pregnancy is defined as having a positive foetal heart action nine or more weeks after the first positive pregnancy test.	approximately 3.5 months from study start (at least 9 weeks after first positive pregnancy test)	No
Secondary	Number of Follicles at hCG Administration	Number of follicles >=17 mm diameter detected by pelvic ultrasound examination at day of hCG administration.	approximately day 10	No
Secondary	Average Follicle Diameter at hCG Administration		approximately day 10	No
Secondary	Number of Cumulus-oocyte Complexes Retrieved	Cumulus-oocyte complexes are oocytes with surrounding cumulus cells.	approximately day 12 after study start	No
Secondary	Number of Pronuclear Oocytes	Pronuclear oocytes are fertilized oocytes.	approximately day 13 after study start	No
Secondary	Number of Participants With Pronuclear Stage Oocytes at Each Quality Grade	The count of participants with different quality grades of pronuclear stage oocytes is offered. Pronuclear stage oocytes are categorized into seven grades (0A, 0B, 1-5) representing different patterns of pronuclear morphology, according to the German Pronuclear Morphology Study Group. 0A is the highest quality oocyte and grade 5 is the lowest quality.; Participants can have pronuclear stage oocytes of different grades and therefore are counted more than once.	approximately day 13	No
Secondary	Number of Embryos Transferred	Mean number of embryos transferred 2-3 days following oocyte retrieval.	approximately day 14	No
Secondary	Best Quality of an Embryo Transferred	Embryo quality was measured by the following grades: Grade 1: Evenly sized cells, regular cleavage, no fragmentation; Grade 2: Regular or slightly irregular cleavage, <=20% fragmentation; Grade 2.5: Regular or slightly irregular cleavage, >20%and <=50% fragmentation; Grade 3: Irregular cleavage, >50% fragmentation, >1 intact cell; Grade 4: Extensive fragmentation, only 1 cell intact; Grade 5: Totally fragmented, no viable cells.; Grade 1 represents the healthiest embryos and Grade 5 embryos are not viable.	approximately day 14	No
Secondary	Number of Frozen Oocytes at Pronuclear Stage	No more than three normally developed embryos were transferred 2-3 days after oocyte retrieval. Other normally developed embryos were frozen.	approximately day 14	No
Secondary	Endometrial Thickness on Day of hCG Administration	Endometrial thickness was assessed by pelvic ultrasound on the day of hCG administration.	approximately day 10	Yes
Secondary	Estradiol (E2) Levels on Day of hCG Administration		approximately day 10	No
Secondary	Percentage of Participants With Successful Embryo Transfer		approximately day 18	No
Secondary	Number of Days Stimulated With Gonadotrophins	Number of days in which gonadotrophins were administered until hCG criteria were met. If hCG criteria were not met by day 13, the participant was withdrawn from the study.	Day 1 up to Day 12	No
Secondary	Number of Ampoules of Gonadotrophins Used	Number of ampoules of gonadotrophins used with the goal of reaching hCG criteria. Each ampoule contained 75 IU of either menotrophin or follitrophin alpha.	Day 1 up to Day 12	No
Secondary	Percentage of Participants With Clinical Pregnancy 6 Weeks After the First Positive Pregnancy Test	A pelvic ultrasound scan was performed approximately 6 weeks after the first positive pregnancy test and the presence of an active foetal heart action indicated a clinical pregnancy.	approximately 2.5 months from start of study, 6 weeks after first positive pregnancy test	No
Secondary	Summary of Pregnancy Outcome	Pregnancy outcomes were reported at the optional long-term follow up visit.	up to 10 months	No